Cure My Disease

Don't miss your cure!

 Log in / Sign up

Metformin's Anti-Aging effects may depend on your insulin sensitivity

NCT ID NCT04264897

Knowledge-focused Sponsor: Oklahoma Medical Research Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study looked at whether the diabetes drug metformin can slow aging in people without diabetes. Researchers wanted to see if the drug's effects depend on whether a person is insulin sensitive or insulin resistant. Over 12 weeks, 101 adults aged 40-75 took either metformin or a placebo, and their insulin sensitivity, blood sugar, and muscle cell function were measured. The goal was to understand who might benefit most from metformin as an anti-aging treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

166 people

The number who actually took part.

Started

Jul 2020

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 40-75 years of age (inclusive) * Free of chronic disease * Comprehension of the protocol as indicated by an ability to respond to questions about the study after reading the consent form. * Able to use and be contacted by telephone. * Able to speak, read, and understand English, and complete a questionnaire in English * Independently mobile Exclusion Criteria: * Pregnancy * Heart disease (history, abnormal ECG, abnormal stress ECG) * Cerebrovascular disease (history) * Cancer (history) * Chronic respiratory disease (history, forced expiratory volume at one second/forced vital capacity \[FEV1/FVC\] \< 70, FEV1 \< 80% predicted) * Chronic liver disease (history, alanine transaminase \[ALT\] \> 52 IU/L) * Diabetes (history, HbA1C ≥ 6.5, fasting blood glucose≥126 mg/dl, oral glucose tolerance test \[OGTT\] ≥ 200 mg/dl at 2 hrs) * Impaired kidney function (eGFR ,45 mL/min) * B12 lab values outside of normal range (\<193 or \>982 pg/mL) * Alzheimer's (history) * Chronic kidney disease (history, abnormal blood kidney panel including serum creatinine \> 1.4) * Problems with bleeding, on medication that prolongs bleeding time (if subject cannot safely stop prior to biopsy) * Those on glucose lowering drugs * Those planning to have imaging that requires intravenous contrast dye (within 6 weeks) or are on any of the following medications since they are contraindicated with the use of metformin: Dofetilide, Lamotrigine, Pegvisomant, Somatropin, Trimethoprim, Trospium, Gatifloxacin, Cephalexin, Cimetidine, Dalfampridine * Tobacco use * Allergies to lidocaine or metformin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Disease Insulin Resistance mitochondrial disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging Chronic disease Insulin resistance Insulin sensitivity Mitochondria

Contacts and locations

Locations

  • University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources

    Oklahoma City, Oklahoma, 73104, United States

  • University of Wisconsin-Madison

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.